Understanding resistance to venetoclax in chronic lymphocytic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather medical information and biological samples from patients with refractory or relapsed chronic lymphocytic leukemia (CLL) who are undergoing or have undergone treatment with venetoclax. The focus is on evaluating the frequency of resistance mechanisms, including BCL2 mutations and changes in energy metabolism. By analyzing blood, bone marrow, and lymph node samples, the study seeks to provide insights into how CLL can resist venetoclax treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age greater than or equal to 18 years old;
* chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
* refractory and/or relapsed disease during or after venetoclax treatment;
* tumor samples available.
* Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
* Patients must be able to express their opposition to be enrolled in this study, if need be.
* Patients must be affiliated at the French Social Security system

Exclusion Criteria:

Patients of their legal guardians refusing to participate

\-

Where it's running

• CHU de Reims
  Reims, France Recruiting
• CHU d'Amiens
  Amiens, France Not yet recruiting
• CHU de Besançon
  Besançon, France Not yet recruiting
• Hopital AVICENNE
  Bobigny, France Not yet recruiting
• CHU clermont-ferrand
  Clermont-Ferrand, France Not yet recruiting
• CHU de Clermont Ferrand
  Clermont-Ferrand, France Not yet recruiting

Study contacts

• Principal investigator: Romain GUIEZE — University Hospital, Clermont-Ferrand
• Study coordinator: Lise Laclautre
• Email: promo_interne_drci@chu-clermontferrand.fr
• Phone: 334.73.754.963

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Comparing BGB-16673 to standard treatments for chronic lymphocytic leukemia

  This study is testing a new treatment called BGB-16673 to see if it works better than standard options for people with chronic lymphocytic leukemia who have already tried other therapies.

  Recruiting at 132 sites Phase 3 BeOne Medicines · Jonesboro, Arkansas and 131 other locations · NCT06846671

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Investigating a new dosing schedule for sonrotoclax in blood cancer treatment

  This study is testing new ways to give the drug sonrotoclax to see if it can safely help people with chronic lymphocytic leukemia (CLL) feel better.

  Recruiting at 22 sites Phase 1/2 BeOne Medicines · Tampa, Florida and 21 other locations · NCT06697184

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.